Investing News NetworkMay 14, 2024Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER trial rationale and design also accepted for publication in the journal ESC Heart FailureARCHER trial has now exceeded 85% of target patient enrollment MAvERIC-Pilot Phase II study investigating CardiolRx™ for recurrent pericarditis expected to report topline results in early June 2024Cardiol Therapeutics Inc.

投资新闻网2024年5月14日，介绍范围包括随机分配到评估急性心肌炎患者CardiolRx™的II期研究的前50名患者的试验设计，基本原理和盲法基线数据ARCHER试验基本原理和设计也被接受发表在ESC心力衰竭杂志上ARCHER试验现已超过目标患者登记的85%MAvERIC试验II期研究调查CardiolRx™治疗复发性心包炎，预计将于2024年6月初报告终点结果Cardiol Therapeutics Inc。

(NASDAQ: CRDL) (TSX: CRDL) ('Cardiol' or the 'Company'), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced its Phase II randomized, double-blind, placebo-controlled trial evaluating the impact of CardiolRx™ on myocardial recovery in patients with acute myocarditis ('ARCHER') was the subject of an oral presentation at the World Congress on Acute Heart Failure 2024, May 11 - 14 in Lisbon, Portugal - the annual congress of the Heart Failure Association of the European Society of Cardiology ('ESC').

（纳斯达克：CRDL）（TSX:CRDL）（“Cardiol”或“公司”）是一家临床阶段生命科学公司，专注于用于治疗心脏病的抗炎和抗纤维化疗法的研究和临床开发，今天宣布了其II期随机，双盲，安慰剂对照试验，评估CardiolRx™对急性心肌炎患者心肌恢复的影响（“ARCHER”）是2024年5月11日至14日在葡萄牙里斯本举行的世界急性心力衰竭大会（the World Congression on acute heart Failure 2024）上的口头报告主题-欧洲心脏病学会心力衰竭协会（ESC）年会。

The trial design, rationale, and blinded baseline data on the first 50 patients randomized into ARCHER was presented by Univ.-Prof. Dr. med. Carsten Tschöpe from the Berlin Institute of Health - Charité, on behalf of the ARCHER steering committee comprising distinguished thought leaders in heart failure and myocarditis from international centers of excellence who contributed to the design and execution of ARCHER.

柏林卫生研究所（Berlin Institute of Health-Charité）的med.Carsten Tschöpe博士代表阿彻指导委员会（ARCHER steering committee）介绍了随机分配到阿彻（ARCHER）的前50名患者的试验设计，基本原理和盲法基线数据，该委员会由国际卓越中心的心力衰竭和心肌炎杰出思想领袖组成，他们为阿彻（ARCHER）的设计和实施做出了贡献。

Concurrent with the presentation, the journal ESC Heart Failure, which is dedicated to advancing knowledge about heart failure worldwide, has accepted the manuscript describing the rationale and .

在演讲的同时，致力于提高全球心力衰竭知识的ESC心力衰竭杂志接受了描述基本原理和理论的手稿。